NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held, Phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company appointed Thomas MacAllister as Vice President of Research and Development, and General Counsel.
“As we begin preparations for commencement later this year of our Phase 3 clinical trial in patients with large hemispheric stroke, Tom’s wealth of CNS-related clinical trial experience will be indispensable,” states Sven Jacobson, CEO of Remedy Pharmaceuticals. “We’re therefore delighted to welcome him to the senior management team.”
Thomas MacAllister, Ph.D., JD, has over 25 years of experience in business development, preclinical and clinical development, regulatory strategy, intellectual property and commercialization. He has assembled and led a team that took a program for severe traumatic brain injury from concept through the completion of a Phase 3 clinical trial. Prior to joining Remedy Pharmaceuticals, Dr. MacAllister served as the Chief Executive Officer of Argentum Pharmaceuticals, for whom he developed new business models to reduce the cost of drugs to the healthcare system. He also served as Chief Executive Officer and General Counsel at BHR Pharma and Chief Development Officer at Besins Healthcare SA where he was primarily focused on drug development and oversaw research and development and the intellectual property department. He is an attorney licensed to practice law in the Commonwealth of Virginia, the District of Columbia and before the United States Patent & Trademark Office.
“I am excited to join the Remedy Pharmaceuticals at this pivotal time,” notes Thomas MacAllister. “I believe that the Company’s lead product, CIRARA, represents a significant opportunity to define the treatment of CNS-related edema, and thus save and improve the lives of countless patients for whom there are currently no effective therapies. I look forward to helping advance this novel compound through clinical development.”
CIRARA™ is a patented, high affinity inhibitor of Sur1-Trpm4 channels, discovered by University of Maryland neurosurgeon Dr. J. Marc Simard. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.